While the early week buzz centered around the U.S.-China trade agreement, another critical development unfolded quietly but forcefully. President Trump signed an Executive Order targeting what he called “Big Pharma price gouging,” with the intention of cutting prescription drug prices by a sweeping 80% to 90%.
The order, finalized Monday, May 12, proposed a “most favored nation” clause, one that would force the U.S. to match the lowest drug prices offered anywhere in the world. The policy sent shockwaves through the pharmaceutical sector, prompting immediate concerns over potential revenue hits.
